Followers | 568 |
Posts | 15097 |
Boards Moderated | 0 |
Alias Born | 12/01/2013 |
![](https://investorshub.advfn.com/uicon/433122.png?cb=1629776078)
Thursday, March 04, 2021 12:54:08 PM
The Indian government approved the use of the COVAXIN vaccine, made by the Indian company Bharat Biotech, on Jan. 3 – while clinical trials were ongoing, and before efficacy data was out. Scientists, public health experts and opposition politicians expressed concern.
Many called the move premature. Some accused India of acting out of nationalism. The Bharat Biotech formula has been billed as India's first "indigenous" vaccine.
Critics cautioned India to wait for data from phase 3 clinical trials.
Now, that data is out.
Late Wednesday, Bharat Biotech released interim data showing its vaccine prevents COVID-19 in 81% of patients who receive two doses. The phase 3 clinical trial involved 25,800 subjects, making it the largest ever in India, the company said.
Trials are still ongoing, and further data is needed for a "final analysis," it said. But Bharat Biotech's chairman said this interim data "demonstrates high clinical efficacy."
"Today is an important milestone in vaccine discovery, for science and our fight against coronavirus," Dr. Krishna Ella said in a statement. He added that the vaccine also shows "significant immunogenicity against the rapidly emerging variants."
https://www.npr.org/sections/coronavirus-live-updates/2021/03/04/973585265/data-show-indias-homegrown-covid-19-vaccine-works-2-months-after-it-was-approved
Recent OCGN News
- Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease • GlobeNewswire Inc. • 06/21/2024 11:00:00 AM
- Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication • GlobeNewswire Inc. • 06/20/2024 10:30:31 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/18/2024 08:29:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 08:31:02 PM
- Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic Atrophy • GlobeNewswire Inc. • 05/31/2024 12:36:49 PM
- Ocugen to Present at BIO International Convention 2024 • GlobeNewswire Inc. • 05/29/2024 11:15:00 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 05/28/2024 08:05:59 PM
- Ocugen Set to Join Russell 3000® Index Effective June 28, 2024 • GlobeNewswire Inc. • 05/28/2024 11:02:39 AM
- Ocugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024 • GlobeNewswire Inc. • 05/20/2024 11:00:52 AM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/17/2024 08:30:54 PM
- Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy • GlobeNewswire Inc. • 05/15/2024 10:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 07:54:50 PM
- Ocugen Provides Business Update with First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/14/2024 12:00:25 PM
- US Futures Remain Steady Amid Wall Street Caution Ahead of April PPI Report • IH Market News • 05/14/2024 11:18:01 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 10:32:02 AM
- Form 8-A12G - Registration of securities [Section 12(g)] • Edgar (US Regulatory) • 05/10/2024 08:15:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/10/2024 08:14:11 PM
- Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common Stock • GlobeNewswire Inc. • 05/10/2024 08:05:06 PM
- Ocugen to Present at May 2024 Investor Conferences • GlobeNewswire Inc. • 05/10/2024 11:45:07 AM
- Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/03/2024 11:30:05 AM
- Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress • GlobeNewswire Inc. • 05/02/2024 11:15:46 AM
- Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024 • GlobeNewswire Inc. • 04/29/2024 10:45:00 AM
- UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting • GlobeNewswire Inc. • 04/26/2024 01:05:24 PM
- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting • GlobeNewswire Inc. • 04/26/2024 10:30:40 AM
- Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy • GlobeNewswire Inc. • 04/19/2024 11:13:05 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM